Clinical utility of [ 18 F]fluoroestradiol (FES) PET/CT to guide second-line treatment decision in patients with ER-positive HER2-negative metastatic breast cancer progressing on first-line endocrine therapy.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.1059
Abstract: 1059 Background: Second line treatment options for patients with ER+/HER2- metastatic breast cancer (MBC) after progression on 1 st line endocrine therapy (ET) continue to expand with novel endocrine agents (oral SERDs) and combination therapies… read more here.
Keywords: line treatment; line; fes uptake; fes pet ... See more keywords